Aplastic Anemia

Rutuja S. Devkar, Shivani V. Mohite, Dhanushree M. Gosavi, Ravi P. Barkade

Abstract: **Aplastic anemia (AA) is an uncommon, potentially fatal, and diverse blood condition. The aplastic anemia pathogenesis. The ratio of men to women is roughly 1:1. While aplastic anemia affects people of all ages, there is a slight peak in incidence that is seen in children. Aplastic anemia can be explained by either intrinsic abnormality of marrow progenitors or extrinsic immune-mediated suppression of hematopoietic stem cells. An unsuccessful bone marrow transplant can cure the underlying illness.A traditional treatment for marrow failure syndromes is androgen therapy.**

Patients with aplastic anemia have extremely high blood levels of thrombopoietin, but in the presence of interferon-γ, eltrombopag may evade a block to receptor engagement. The most frequent side effects of aplastic anemia are infections, bleeding, or lymph proliferative disorders.

Keywords: Aplastic Anemia, Progenitors.

INTRODUCTION

Aplastic anemia (AA) is an uncommon, potentially fatal, and diverse blood condition. Peripheral cytopenia and trilineage bone marrow (BM) aplasia are the outcomes. A number of additional clinical symptoms, including anemia, bleeding, and infections, are typically the initial signs of AA. While it can happen to anyone at any age, the most vulnerable are the young (between the ages of 10 and 25) and the old (over 60). There have been no discernible gender differences found.[1]

The incidence of AA is less than 2.5/million in the US and Europe, but 2-3 times higher in Asia [2, 3]. Nonetheless, there are differences in the incidence rates of AA in Asia amongst the different nations; rates in China are 7.4/million, in Thailand 3.7–5.0/million, and in Malaysia 4.8/million. Drugs, poisons, and chemicals are examples of environmental elements that can affect the frequency of AA [4].

Aplastic anemia (AA) is a nonmalignant hematologic illness that was first identified by Dr. Paul Ehrlich in 1888 and was further defined by Dr. Anatole Chauffard in 1904. AA is characterized by a damaged, notably hypocellular, and hence inefficient bone marrow [5].

Etiology:

The aplastic anemia pathogenesis. The prevalent disease of bone marrow replaced by fat can be caused by immune system destruction (mostly T cells), physical or chemical injury (iatrogenic; benzene), or a genetic deficiency in a gene essential to immune system regulation and cell integrity maintenance.

Hematopoietic growth factors are represented by the letters HGF, BMT, and IST.

According to specialized studies, the incidence of aplastic anemia is a rare condition that affects two to three instances out of every million people annually; however, in Asian populations, the incidence may be three times greater. It is a disease that primarily affects young people, usually in their first three decades of life, with a median age of roughly 20, however there is a second peak that happens around age 60 [6].



Fig.1-Etiology of aplastic anemia

Epidemiology:

In general, accurate data on the epidemiology of aplastic anemia incidence is not readily available. According to studies, there are between 0.6 and 6.1 cases per million people; the majority of the data used to calculate this rate comes from retrospective reviews of death registries.

The ratio of men to women is roughly 1:1. While aplastic anemia affects people of all ages, there is a slight peak in incidence that is seen in children. The age range of 20 to 25 years old has a second peak[7].

Histopthology:

Patients with aplastic anemia will have noticeably hypocellular bone marrow biopsies. Normal bone marrow tissue is replaced by fibrotic stroma and fat cells. Only plasma cells and stray lymphocytes are left, and the rest lacks bone marrow progenitors.[8]



Fig.2-Histopathology of aplastic anemia

Aplastic anemia can be explained by either intrinsic abnormality of marrow progenitors or extrinsic immune-mediated suppression of hematopoietic stem cells. Hippocampoietic stem cells that have sustained damage develop into self-reactive T-helper cells (T1), which release the cytokine interferon-? (IFN?) Additionally, tumour necrosis factor (TNF) kills and suppresses additional hematopoietic stem cells by initiating a cytotoxic cascade. The glucose phosphate inositol (GPI)-linked protein on cell membranes appears to be one of the specific antigens that T1 cells target; this is the mechanism underlying pancytopenia in PNH. Apoptosis and death pathway genes are also overexpressed.

Additionally, two-thirds of patients with idiopathic aplastic anemia respond to immunosuppressive therapy that targets T-cells, and patients with graft-versus-host disease develop aplasia in the presence of healthy bone marrow progenitors.[9]

Symptoms:

Aplastic anemia manifests at any age and is equally distributed across racial and gender categories. thrombocytopenia, ecchymoses, mucosal bleeding, petechiae, neutropenia, frequent and persistent minor infections, and sudden onset febrile illness are symptoms associated with the absent cell lineage.

When splenomegaly is present, it indicates a different diagnosis because it is not seen. Labs will show reticulopodia, neutropenia, and thrombocytopenia along with macrocytic normochromic anemia. Cytologic abnormalities are required to rule out the possibility of an underlying hematologic process.[10]

Diagnosis:

Acquired AA as a result of systemic connective tissue disease, blood cancer, thymoma, pregnancy, exposure to ionizing radiation, chemicals, medications with potent myelosuppressive effects, or viral infections (e.g., HCV, HIV, and herpesviridae).

The majority of the time, acquired AA is the consequence of an autoimmune response to hematopoietic stem cells (increased T cell cytotoxicity and increased Th1 cell production of cytokines that inhibit hematopoiesis) and the Fas/Fas-ligand system's induction of apoptosis. All hematopoietic lines are impaired in this disease, which typically coexists with anemia, leukopenia, and thrombocytopenia.[12]

The identification of pancytopenia in peripheral blood and bone marrow trepanobioptate atrophy of normal hematopoiesis in the absence of dysplasia are the foundations for the diagnosis of AA. Bone marrow cellularity is not more than 25% of the average age. Peripheral blood morphology, erythrocyte macrocytosis, mono- or bipenia, and lymphocyte count within reference ranges recorded during the initial phases of the illness. The haematological values are used to classify the severity of AA.[13]



Fig.3- Diagnosis of aplastic anemia

Causes:

Red, white, and platelet blood cells are produced by bone marrow stem cells. Damage is done to stem cells in aplastic anemia.

Consequently, the bone marrow is either hypoplastic—containing few blood cells—or empty (aplastic).



Fig.4- Attack on bone marrow

Bone marrow:
Your bones contain a red, spongy substance called bone marrow, which is where blood cells are made. The most frequent cause of aplastic anemia is an immune system attack on bone marrow stem cells. Other elements that can harm bone marrow and impact the production of red blood cells are as follows:

Radiations and Chemotherapy treatments:

While these cancer-fighting therapies kill cancer cells, they can also damage healthy cells, including stem cells in bone marrow. Aplastic anemia can be a temporary side effect of these treatments.

Exposure to carcinogenic substances:

Carcinogenic substances, including some found in insecticides and pesticides, as well as gasoline's benzene, have been connected to aplastic anemia. If the chemicals that caused your illness are not repeatedly exposed to, your type of anemia may get better.

Drug usage: Certain drugs, like those prescribed for rheumatoid arthritis and some antibiotics, have the potential to induce aplastic anemia.

Autoimmune disorders: Your bone marrow may contain stem cells if you have an autoimmune disorder, which is characterized by your immune system attacking healthy cells.

Viral infection: Aplastic anemia can arise as a result of bone marrow-related viral infections. Aplastic anemia has been associated with a number of viruses, including HIV, cytomegalovirus, parvovirus B19, Epstein-Barr, and hepatitis.

Pregnancy: During pregnancy, your bone marrow may be attacked by your immune system.

Unknown factors: The cause of aplastic anemia (idiopathic aplastic anemia) is frequently unknown to medical professionals.[14]

Treatment:

• Transplanting bone marrow (BMT):

An unsuccessful bone marrow transplant can cure the underlying illness. Graft rejection and graft-versus-host disease (GVHD), as well as the lack of suitable donors, have restricted the use of transplants.

When a histocompatible sibling donor is used promptly after diagnosis, transplantation is always preferred for young patients with immune aplastic anemia. The outcomes are excellent, with over 90% long-term survival in young children and over 80% in adolescents, as well as a low rate of short- and long-term complications.

Even though sibling donor transplants are becoming more common among older adults, the outcomes have not improved over the years, with about 50% of recipients over 40 years old—nearly three times higher than in children—receiving the transplant. In addition, African-Americans fare worse than Caucasians.

Given that peripheral blood causes more GVHD, marrow is the recommended source. Radiation is avoided, especially in children, and rabbit ATG is frequently added to the conditioning regimen.

• Suppression of immunity:

All patients can receive immunosuppressive therapy, which is less difficult than transplantation but may have late effects because it does not replace the immune system or damaged bone marrow. Relapses that happen frequently can be treated, but they require long-term cyclosporine use from the patient.

Even after stable blood count recovery, "clonal evolution," or the subsequent development of MDS or AML, is more dangerous. In approximately 15% of patients with aplastic anemia during the ten years after the start of immunosuppression, clonal evolution most commonly presents as a cytogenetic abnormality, typically involving the loss of all or part of chromosome 7. The poor prognosis associated with chromosome 7 aneuploidy prompts efforts toward transplantation.

• Androgens:

A traditional treatment for marrow failure syndromes is androgen therapy. Androgens are standard treatment for many constitutional syndromes, despite the fact that they are generally thought to be much less effective in severe aplastic anemia than are immunosuppressive strategies. Sex hormones cause the telomerase gene to be expressed more in mice and in cell cultures.

High doses of the synthetic androgen danazol improved blood counts in patients with telomere

disease and also seemed to reverse accelerated telomere attrition in a recent prospective trial.

• Stimulation of Stem Cells:

Long-term results and response rates have not changed in attempts to enhance ATG by adding androgens, granulocyte colony stimulating factor, mycophenolate, or rapamycin. In cases of aplastic anemia, hematopoietic growth factors are ineffective.

Elevated numbers of progenitor cells, CD34 cells, and bone marrow cellularity indicate that eltrombopag directly affects bone marrow stem cells. Patients with aplastic anemia have extremely high blood levels of thrombopoietin, but in the presence of interferon-γ, eltrombopag may evade a block to receptor engagement (Alvarado and Larochelle, personal communication) [15].

Risk Factors:
Aplastic anemia is rare. Factors that can increase risk include:

- Treatment with high-dose radiation or chemotherapy for cancer.
- Exposure to toxic chemicals
- The use of some prescription drugs — such as chloramphenicol, which is used to treat bacterial infections, and gold compounds used to treat rheumatoid arthritis.
- Certain blood diseases, autoimmune disorders and serious infections.
- Pregnancy, rarely.[16]

Managements:
Patients with moderate AA are treated individually, taking into account their symptoms, the severity of their illness, and any changes in the degree of cytopenia over time. In many cases, close observation is necessary, particularly in cases where transfusion needs and symptoms are not great. Conversely, even when SAA or vSAA are successfully treated, more than 70% of patients will pass away within a year.

G-CSF or erythropoietin initial trials shouldn't be administered to patients.Although there are many different forms of treatment, immunosuppressive therapy (IST) is still the most widely utilized initial course of treatment. The patient's age and the degree of aplastic anemia determine the prognosis.[17]



Fig.5-Flow chart of therapy

Prevention:

Preventive antibiotic therapy is controversial; while it lowers mortality in some patients, it also raises the risk of drug resistance and alters the intestinal microbiota negatively. Some antibacterial medications are also myelosuppressive.

Avoiding Pneumocystis jirovecii-caused pneumonia during lymphopenia following ATG treatment is important. Trimethoprim-sulfamethoxazole should be substituted with an alternative medication because of its myelosuppressive properties.In patients with VSAA, antimicrobial prevention with quinolone antibiotics may lower the risk of Gram-negative sepsis; however, routine antibiotic use is not advised to prevent the development of antibiotic resistance in patients with higher neutrophil counts [18]. Without waiting for the findings of bacteriological testing, a patient with AA who has a fever needs to be admitted to the hospital and treated right away.

First, β-lactam antibiotics combined with aminoglycosides are given to treat Pseudomonas aeruginosa. If the patient still has a fever after two days on antibiotics, it may be a fungal infection. In this case, intravenous antifungal medications such as voriconazole, capsaicin, or Aspergillus (amphotericin) should be started right away.Particularly in cases of sinusitis or inflammatory changes in the lungs, fungus should be suspected as the cause. Consider short-term treatment with granulocyte colony-stimulating factor (G-CSF) if response to antibiotics and antifungal agents is absent. G-CSF routine use outside of eutropenic fever episodes is debatable.

Patients who do not respond to anti-infective therapy may benefit from granulocyte concentrate treatment. However, evidence of their use's evident benefits has not yet been established [19].

Due to the possibility of immune activation, the advantages and disadvantages of vaccinations in AA are still debatable. Certain AA guidelines advise against vaccination unless a patient has undergone allo-HSCT.

Due to the possibility of immunological activation, vaccination efficacy for AA patients is still debatable. Certain AA guidelines advise against vaccination unless a patient has undergone allo-HSCT. [20]

Care for Patients:

Following IST and allo-HSCT therapy, patients need long-term symptomatic care, which may include transfusions of red blood cells and platelets as well as treatment for any infectious consequences. These treatments might be the only ones administered to extremely old patients or those with moderate pancytopenia.[21]

Transfusions should be used carefully in allo-HSCT patients to lower the chance of donor antigen immunization. It is best to steer clear of blood preparations from siblings or family donors to reduce the possibility of transplant failure brought on by an immune reaction to donor antigens.[22]

In general, low-leukocyte and irradiated products (doses of 25–30 Gy) are used to prevent cytomegalovirus (CMV) infection and to lessen the risk of all immunity and febrile post-transfusion reactions, among other things [23].

A decrease in hemoglobin (HGB) concentration below 6 g/dL is the indication for red blood cell concentrate transfusion administration, and prophylactic platelet transfusions should be given when the patient's platelet count (PLT) falls below 10×109/L. To lower the risk of potentially fatal bleeding, the PLT number should be kept above 20×109/L when concomitant complications like fever or bleeding are present [24].

Complications:

The most frequent side effects of aplastic anemia are infections, bleeding, or lymph proliferative disorders. Surveillance and symptomatic therapy, such as antibiotics, chemotherapy, and/or transfusions, are used to treat these [25].

Prognosis and survival:

Patients with aplastic anemia have a high one-year mortality rate of nearly 70% if they are not treated [26]. The typical clinical course of pancytopenia involves a range of complications, including bleeding, infections, relapses, and clonal evolution. Nevertheless, with the growing availability of hematopoetic stem cell transplants and efficient immunosuppressive therapy, survival rates have reached as high as 80%. [27]

Drugs and their adverse reaction:

- Sargramostim Injection:

•Redness, swelling, bruising, itching or a lump in the area where the medication was injected

•Bone, joint, or muscle pain

•Headache, nausea, vomiting, diarrhea, stomach pain, mouth sores, loss of appetite, hair loss.

- Filgrastim Injection:

• Pain in the left upper part of the stomach or the tip of the left shoulder fever, shortness of breath, trouble breathing, fast breathing.

• Trouble breathing, coughing up blood, fever, abdominal pain, back pain, feeling unwell.

•swelling of stomach area or other swelling, decreased urination, trouble breathing, dizziness, tiredness

•rash, hives, itching, swelling of the face, eyes, or mouth, wheezing, shortness of breath

•unusual bleeding or bruising, purple markings under the skin, red skin

•decreased urination, dark or bloody urine, swelling of the face or ankles

painful, urgent, or frequent urination.

- Epoetin Alfa Injection:

•Headache, joint or muscle aches, pain, or soreness, nausea, vomiting, weight loss.

•difficulty falling asleep or staying a sleep, depression, muscle spasms, runny nose, sneezing, and congestion fever, cough, or chills, redness, swelling, pain, or itching at the injection spot.[28]

CONCLUSION

Aplastic anemia is a rare, life threatening syndrome of bone marrow failure. The pathogenesis of aplastic anemia is directly related to the destruction of hematopoietic stem cells. The treatment of severe

aplastic anemia, whether by allogeneic stem cells transplantation or immunosuppression, has improved dramatically over the years, and long term survival of more than 75% of patient can be anticipated with either therapy.

Additional studies using epidemiology, basic and clinical research to carefully analyze the etiology and pathology of aplastic anemia are required. In addition, individualized treatment strategies to appropriately treat patients with aplastic anemia are required to improve their prognosis, while simultaneously paying attention to the patient's quality of life.

REFERENCE

1.Bär C, Povedano JM, Serrano R, et al. Telomerase gene therapy rescues telomere length, bone marrow aplasia, and survival in mice with aplastic anemia. Blood. 2016; 127:1770–1779. doi: 10.1182/blood-2015-08-667485 [Crossref] [PubMed] [Web of Science ®]

2.Fan R, Wang W, Wang XQ, et al. Incidence of adult acquired severe aplastic anemia was not increased in Shanghai, China. Ann Hematon .2011; 90:1239–1240. doi: 10.1007/s00277-011-1168-6 [Crossref] [PubMed] [Web of Science ®],

3.Akram Z, Ahmed P, Kajigaya S, et al. Epidemiological, clinical and genetic characterization of aplastic anemia patients in Pakistan. Ann Hematol. 2019; 98:301–312. doi: 10.1007/s00277-018-3542-z [Crossref] [PubMed] [Web of Science ®],

4.Li SS, Hsu YT, Chang C, et al. Incidence and treatment outcome of aplastic anemia in Taiwan-real-world data from single-institute experience and a nationwide population-based database. Ann Hematol. 2019; 98:29–39.doi: 10.1007/s00277-018-3486-3 [Crossref] [PubMed]

5.Nakagawa MM, Rathinam CV. Constitutive activation of the canonical NF-kappaB pathway leads to bone marrow failure and induction of erythroid signature in hematopoietic stem cells. Cell Rep. 2018;25:2094–2109. e2094. doi: 10.1016/j.celrep.2018.10.071 [Crossref] [PubMed] [Web of Science ®]

6. Moore, C. A. (2023, July 17). Aplastic anemia. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK534212

7. Li SS, Hsu YT, Chang C, Lee SC, Yen CC, Cheng CN, Chen JS, Lin SH, Chang KC, Chen TY. Incidence and treatment outcome of aplastic anemia in Taiwan-real-world data from single-institute experience and a nationwide population-based database. Ann Hematol. 2019 Jan; 98(1):29-39. [PubMed]

7.Vaht K, Göransson M, Carlson K, Isaksson C, Lenhoff S, Sandstedt A, Uggla B, Winiarski J, Ljungman P, Brune M, Andersson PO. Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000-2011. Haematologica. 2017 Oct102 (10):1683-1690. [PMC free article] [PubMed]

8. Moore, C. A. (2023, July 17). Aplastic anemia. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK534212/

9.Schoettler ML, Nathan DG. The Pathophysiology of Acquired Aplastic Anemia: Current Concepts Revisited. Hematol Oncol Clin North Am. 2018 Aug; 32(4):581-594. [PMC free article] [PubMed]

10.Yamazaki H. [Acquired aplastic anemia: recent advances in pathophysiology and treatment]. Rinsho Ketsueki. 2018; 59(6):711-715. [PubMed]

https://www.ncbi.nlm.nih.gov/books/NBK53421

Shimamura A. Aplastic anemia and clonal evolution: germ line and somatic genetics. Hematology Am Soc Hematol Educ Program 2016; 2016:74-82. [Crossref] [PubMed]

11. Yamazaki H. Acquired aplastic anemia: recent advances in] pathophysiology and treatment. Rinsho Ketsueki 2018; 59:711-5. [PubMed]

12. Shimamura A. Aplastic anemia and clonal evolution: germ line and somatic genetics. Hematology Am Soc Hematol Educ Program 2016; 2016:74-82. [Crossref] [PubMed]

13. Dolberg OJ, Levy Y. Idiopathic aplastic anemia: diagnosis and classification. Autoimmun Rev 2014; 13:569-73. [Crossref] [PubMed] Dufour C, Pillon M, Socie G, et al. Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant. Br J Haematol 2015; 169:565–73. [PubMed] [Google Scholar]

14. https://www.mayoclinic.org/diseases-conditions/aplastic-anemia/symptoms-causes/syc-20355015

15.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467577/

16. https://www.mayoclinic.org/diseases-conditions/aplastic-anemia/symptoms-causes/syc-20355015

17.https://www.ncbi.https://medcraveonline.com/JCPCR/aplastic-anemia--a-quick-review.htmlnlm.nih.gov/pmc/articles/PMC6467577/
18. Gafter-Gvili A, Fraser A, Paul M, et al. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142:979-95. [Crossref] [PubMed]
19. Quillen K, Wong E, Scheinberg P, et al. Granulocyte transfusions in severe aplastic anemia: an eleven-year experience. Haematologica 2009; 94:1661-8. [Crossref] [PubMed]
20. Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol 2016; 172:187-207. [Crossref] [PubMed]
21. Höchsmann B, Moicean A, Risitano A, et al. Supportive care in severe and very severe aplastic anemia. Bone Marrow Transplant 2013; 48:168-73. [Crossref] [PubMed]
22. Champlin RE, Horowitz MM, van Bekkum DW, et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood 1989; 73:606-13. [Crossref] [PubMed]
23.Fast LD. Developments in the prevention of transfusion-associated graft-versus-host disease. Br J Haematol 2012; 158:563-8. [Crossref] [PubMed]
Dzik WH. Leucoredution of blood components. Curr Opin Hematol 2002; 9:521-6. [Crossref] [PubMed]
24.British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematol 2003; 122:10-23. [Crossref] [PubMed]
25.https://www.ncbi.nlm.nih.gov/books/NBK534212/
26. Young NS (2000) Aplastic anaemia. The Lancet. 2013; 346 (8969):228–232.
27 .Höchsmann B, Moicean A, Risitano A, et al. Supportive care in severe and very severe aplastic anemia. Bone Marrow Transplant. 2013; 48 (2):168–173.
28.https://medlineplus.gov/druginfo/meds/a693005.html